Icepan-L SR Capsule is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Pantoprazole 40 mg, designed for the management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and dyspepsia. Pantoprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing effective relief from acid-related conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, improving patient compliance by reducing dosing frequency. Icepan-L SR Capsule is indicated for the treatment of functional dyspepsia, gastroesophageal reflux disease, and other acid-peptic disorders where both acid suppression and prokinetic effects are desired. It should be used under medical supervision, considering contraindications such as hypersensitivity to components and caution in patients with hepatic or renal impairment. Common adverse effects may include headache, dizziness, and mild gastrointestinal disturbances. Regular monitoring is recommended to assess therapeutic response and detect any potential side effects.